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N-Phenylputrescine (NPP): A Natural Product Inspired Amine 
Donor for Biocatalysis 
Catherine A. McKenna,a Mária Štiblariková,b Irene De Silvestro,c Dominic J. Campopiano,a* and 
Andrew L. Lawrencea*  
The synthesis of chiral amines in enantioenriched form is a keystone reaction in applied chemical synthesis. There is a strong 
push to develop greener and more sustainable alternatives to the metal-catalysed methods currently used in the 
pharmaceutical, agrochemical and fine chemical industries. A biocatalytic approach using transaminase (TA or ATA) enzymes 
to convert prochiral ketones to chiral amines with unparalleled levels of enantioselectivity is highly appealing. However, the 
use of TA enzymes in synthesis is severely hampered by the unfavourable thermodynamics associated with the amine 
donor/acceptor equilibrium. Several ‘smart’ amine donors have been developed that leverage chemical and physical driving 
forces to overcome this challenging equilibrium. Alongside this strategy, enzyme engineering is typically required to develop 
TAs compatible with these non-physiological amine donors and the unnatural reaction conditions they require. We herein 
disclose N-phenylputrescine (NPP) as a readily accessible amine donor, inspired by the biosynthesis of the dipyrroloquinoline 
alkaloids. NPP is compatible with a broad range of synthetically useful TA biocatalysts and performs across an unparalleled 
variety of reaction conditions (pH and temperature). Synthetic applicability has been demonstrated through the synthesis 
of the anti-diabetic drug sitagliptin, delivering the product in excellent enantiopurity using just two equivalents of NPP.
Introduction 
The need to develop more sustainable manufacturing processes 
in the pharmaceutical, agrochemical, and other fine-chemical 
industries has led to an increased interest in biocatalytic 
methods.1–6 By using biocatalysts, enantiopure compounds can 
often be produced in high yield under very mild aqueous 
reaction conditions, but they can suffer from several practical 
limitations and drawbacks.7,8 For example, transaminases (TAs 
or ATAs) provide an environmentally friendly alternative to 
traditional transition-metal catalysed methods for the synthesis 
of chiral amines, which are ubiquitous building blocks in the 
pharmaceutical and agrochemical industries, and find wide 
application as chiral auxiliaries, catalysts, ligands, and resolving 
agents (Fig. 1).9,10 Unfortunately, TA-mediated transamination 
reactions often suffer from unfavourable reaction equilibria, an 
issue that can critically limit many biocatalytic methods.11 We 
herein report a biomimetic solution to this problem, which will 
facilitate the increased use of TA biocatalysts in sustainable 
synthesis. 
Biocatalytic transamination proceeds via a double-
displacement mechanism (ping-pong bi bi mechanism), 
involving the cofactor pyridoxal 5´-phosphate (PLP). Overall, an 
amino group is transferred from an amino donor to a carbonyl 
acceptor (Fig. 2a).15–17 The equilibrium that exists between the 
donor and acceptor can be problematic when applying TA 
biocatalysts in synthesis, particularly when the desired reaction 
is enthalpically unfavourable. Previous strategies for 
overcoming this issue have involved the use of excess amine 
donor and leveraging various chemical and/or physical 
phenomena to drive the equilibrium forward.18,19 The most 
commonly employed amine donors, despite their unfavourable 
reaction equilibria, are L-alanine and iso-propylamine (i-PrNH2). 
L-Alanine is a widely accepted natural amine donor whose by-
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product, pyruvate, can be irreversibly consumed through 
coupled enzymatic processes. Although this is an effective 
strategy, it significantly increases production costs at scale.20–23 
i-PrNH2 is widely used in industry because evaporative loss of 
the acetone by-product can be used to drive the equilibrium 
forward.24,25 However, enzyme engineering is typically required 
to improve the stability of the transaminase in the high 
concentrations of i-PrNH2 required to drive the equilibrium 
towards product formation.26 More complex amine donors 
have been developed, such as o-2-(4-nitrophenyl)ethan-1-
amine 1, xylyenediamine 2, , and cadaverine 3, which can be 
very successfully applied in specific settings (Fig. 2b).27–34 These 
‘smart’ amine donors each have their own niche applications, 
such as in colourimetric assays or when tolerance to specific 
reaction conditions is required, but there remains an unmet 
need for a widely accepted and readily available amine donor 
which overcomes the donor/acceptor equilibrium problem.18,35 
While i-PrNH2 is currently used in industrial processes due to 
advancements in enzyme engineering, it is unsuitable in the 
asymmetric synthesis of volatile amines. In a recent review, 
Pavlidis and co-workers stated “…designing industrial processes 
with these enzymes [TAs] is still challenging, due to the fact that 
a universal and discernible amine donor system has not been 
developed”.26  
We took inspiration for the design of a new amine donor from 
the proposed biosynthetic pathway of the plant-derived 
dipyrroloquinoline alkaloids, incargranine B (7) and 
seneciopiperidine (8) (Fig. 2c).36 TA-mediated oxidative 
deamination of an N-arylputrescine 4 is proposed to give an 
enamine 6 and an iminium ion 5 that react together through an 
irreversible Povarov reaction to give the dipyrroloquinoline 
framework. The chemical feasibility of this pathway has been 
demonstrated through our biomimetic total synthesis and 
structural revision of incargranine B 7.36 We herein disclose the 
design and synthesis of N-phenylputrescine 9 (NPP), which 
exploits this irreversible biosynthetic Povarov reaction to 
generate a dipyrroloquinoline by-product 10 that provides a 
thermodynamic driving force in the TA mediated synthesis of 
amines (Fig. 2d). As we envisaged, NPP 9 displaces the 
challenging transamination equilibrium when used in near 
equimolar quantities, is widely accepted by wild-type and 
engineered TA biocatalysts, and performs well under a broad 
range of reaction conditions. 
Fig. 2  (a) TA-mediated synthesis of chiral amines. (b) Example of amine donors L-alanine, i-PrNH2 and 1–3 (blue) with their respective by-products (red). (c) Inspiration 
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Results & Discussion 
Synthesis of NPP (9) 
NPP 9 can be synthesised through a simple two-step process 
from commodity chemicals;37 alkylation of aniline with 4-
chlorobutyronitrile followed by reduction with borane gives 
NPP free base 9, as an oil, in 80% yield on a gram scale. 
Alternatively, the hydrochloride salt, which is an easy to handle 
solid, can be similarly accessed in >80% yield in >25 g batches. 
This has allowed us to easily prepare over 100 g of NPP 9 salt, 
which can be stored under ambient conditions with no special 
precautions required (see Supplementary Section 2.2 and 2.3 
for details). 
 
Enzyme-coupled activity screen of NPP (9) 
We established NPP 9 as a suitable amine donor using 
Halomonas elongata TA (HEWT) with pyruvate as amine 
acceptor.38,39 An adaptation of the L-amino acid oxidase (L-AAO) 
and horse radish peroxidase (HRP) coupled colourimetric assay 
was used to investigate the kinetics of L-alanine formation.40,41 
The results were fitted to Michaelis–Menten kinetics and NPP 9 
displayed a KM of 10.4 ± 1.4 mM. In comparison, (S)-
methylbenzylamine 14, under the same reaction conditions, has 
a KM of 9.4 ± 2.2 mM (see Supplementary Section 2.5 for more 
details). With evidence that NPP 9 is a good amine donor for this 
TA biocatalyst, our attention turned towards investigating how 
effective NPP 9 is at displacing the donor/acceptor equilibria 
with a variety of TA biocatalysts.  
 
Quantitative screen of NPP (9) with the Codexis® ATA library 
A quantitative screen (using the recommended conditions 
outlined in the Codexis® Amine Transaminase (ATA) screening 
kit) was carried out with 24 commercially available Codexis TAs 
and two wild type TAs (Chromobacterium Violaceum TA (CVTA) 
and HEWT) with benzaldehyde 11 as amine acceptor (Fig. 
3a).42,43 Analysis by HPLC showed all except one of the TA 
biocatalysts accepted NPP 9, with 12 of the 24 Codexis TAs and 
both wild-type TAs giving good yields of benzylamine 13 (Fig.  
3b). With this initial success, the screen was repeated with the 
more challenging acetophenone 12 as amine acceptor. 
Encouragingly, similarly effective yields of methylbenzylamine 
14 product were observed (Fig. 3b). It should be noted that the 
reaction conditions could be optimised for each individual 
biocatalyst if desired. Furthermore, as new TA biocatalysts 
continue to be discovered through metagenomic screening and 
directed evolution, we envisage expanded applications of NPP 
9 in the synthesis of chiral amines.25,44,45 
During this initial screen, we noticed the formation of an off-
white precipitate correlated with activity. This observation was 
investigated further through a scale up of the reaction using 
HEWT with 100 mg of NPP 9, and benzaldehyde 11 as amine 
acceptor. The precipitate was isolated and analysed by NMR, IR 
and MS (see Supplementary Section 2.3 for more details). This 
spectroscopic analysis confirmed the white precipitate was the 
expected dipyrroloquinoline by-product 10 (d.r. 2:1), a 
simplified analogue of incargranine B.36 Interestingly, the 
diastereoselectivity of this biocatalytic reaction was similar to 
that of our biomimetic chemical synthesis of incargranine B 
aglycone,36 suggesting the TA does not provide any additional 
selectivity during the Povarov reaction. The fortuitous 
insolubility of 10 provides an additional driving force for the TA 
reaction and can be used as a simple visual screening method 
for identifying novel TA activity (see Supplementary Fig. S1, 
S17).  
Fig. 3  Quantitative screen of commercial and wild-type TAs with NPP 9 as amine donor. 
(a) TA-mediated transamination of benzaldehyde 11 (Conditions: benzaldehyde 11 (10 
mM) with NPP 9 (10 mM), TA (1 mg/mL), KPi (pH 8, 100 mM), PLP (0.1 mM), DMSO (10%), 
30 (*) or 37 °C, 24 h) or acetophenone 12 (Conditions: acetophenone 12 (10 mM) with 
NPP 9 (20 mM), TA (2 mg/mL) HEPES (pH 7.5, 100 mM), PLP (0.1 mM), DMSO (10%), 30 
(*) or 37 °C, 48 h). (b) Tabulated HPLC yields of benzylamine 13 and methylbenzylamine 
14, relative to the best performing TAs. Reactions were performed in triplicate and errors 
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Optimising the reaction conditions of NPP (9) 
The window of acceptable reaction conditions can limit the 
application of amine donors and hence we turned our attention 
towards screening the applicability of NPP 9 to prepare 
methylbenzylamine 14 over a range of pH and temperatures 
(Fig. 4a). Our previous screen identified ATA-234 and ATA-251 
as providing the highest yields and these commercial TAs were 
thus selected for further study alongside HEWT and CVTA. 
Pleasingly, NPP 9 performed exceptionally well across a broad 
range of reaction conditions when used in near equimolar 
quantities, relative to acetophenone 12 (Fig. 4b,c). This 
compares very favourably to the niche working conditions of 
alternative amine donors. For example, i-PrNH2 needs elevated 
temperatures to facilitate acetone evaporation and cadaverine 
3 requires high pH to drive trimer formation.29,35,46 
 
Activity of NPP (9) with more challenging amine acceptors 
To further explore the effectiveness of NPP 9 as an amine donor 
in comparison to i-PrNH2, we investigated the synthesis of chiral 
amines from more challenging substrates such as p-methoxy 
acetophenone 15 (Fig. 5a) and 1-indanone 17 (Fig. 5b). For this 
screen we selected three commercial and one wild-type 
biocatalysts (ATA-234, ATA-238, ATA-251 and HEWT). We were 
pleased to observe NPP 9 outperformed i-PrNH2 in each case 
under identical reaction conditions (Fig. 5c,d). This reveals the 
potential utility of NPP 9 in applications where i-PrNH2 does not 
perform well. NPP 9 also outperformed cadaverine 3, one of the 
most popular ‘smart’ amine donors used in the field, in the 
transamination of acetophenone 12 (see Supplementary 
Section 2.17 for full details).29, 30 
 
 
Fig. 4  NPP 9 performance over a range of pH and temperatures. (a) General 
scheme of the assay components were unless otherwise stated acetophenone 
12 (10 mM), NPP 9 (11 mM), ATA-251 (2 mg/mL), KPi (pH 8, 100 mM), PLP (0.1 
mM), DMSO (10%), 37 °C, 48 h. (b) Effects on production of 
methylbenzylamine 14 as pH is varied from 6–11. (c) Effects on production of 
methylbenzylamine 14 with NPP 9 as temperature is varied with HEWT, CVTA, 
ATA-234 and ATA-251 (2 mg/mL). *Methylbenzylamine 14 production by HPLC 
normalised relative to that of the best result.  Reactions were performed in 
triplicate and errors determined by standard deviation.
 
Fig. 5  Exploring NPP 9 activity as amine donor with more challenging substrates 15 
and 17. All reactions were carried out in triplicate with TA (2 mg/mL) in HEPES (pH 7.5, 
100 mM), PLP (0.1 mM), DMSO (10%) at 37 °C for 48 h in a sealed system. (a) 
Transamination of p-methoxy acetophenone 15 with i-PrNH2 or NPP 9. (b) 
transamination of 1-indanone 17 with i-PrNH2 or NPP 9. (c) HPLC yield of p-methoxy 
methylbenzylamine 16 produced from transamination of p-methoxy acetophenone 
15 (10 mM) and NPP 9 (green) or i-PrNH2 (yellow) (20 mM). (d) HPLC yield of 1-
indanamine 18 produced from transamination of 1-indanone 17 (10 mM) and NPP 9 
(green) or i-PrNH2 (yellow) (20 mM). HPLC yields of 16 and 18, are relative to the best 
performing TAs. Reactions were performed in triplicate and errors determined by 
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Applying NPP (9) to the synthesis of an industrial target 
We next selected a proof-of-concept target to highlight the 
practical applicability of NPP 9 in the synthesis of complex 
targets. Merck’s commercial synthesis of the antidiabetic drug, 
sitagliptin 20 using a late-stage TA-mediated reductive 
amination is perhaps the most compelling demonstration of the 
power of modern biocatalytic methods. This drug is 
manufactured from ketone 19 using a highly engineered 
Codexis® TA with a high molar excess of i-PrNH2 as amine 
donor.25 We were intrigued as to whether this process could 
instead be conducted using near equimolar NPP 9 as amine 
donor. This was achieved by initially screening the (R)-TAs in the 
Codexis® kit with ketone 19 as amine acceptor. Pleasingly five of 
the eleven TAs showed activity (see Supplementary Section 2.19 
for more details) with ATA-025 displaying the best conversion. 
An optimised reaction was carried out with ATA-025 on a 100 
mg scale to give (R)-sitagliptin 20 in 54% isolated yield (>99% 
ee), with the insoluble by-product 10 easily removed by simple 
filtration through Celite® (Fig. 6, Figs. S42-S47 and 
Supplementary Section 2.24 for more details). This showcases 
the significant practical advantages of using NPP 9 as a versatile 
amine donor in TA-mediated syntheses of chiral amines.  
Conclusions 
The continued demand for a universal amine donor for 
biocatalytic transaminations prompted us to explore how 
nature achieves the biosynthesis of complex natural products 
via TA-mediated pathways. Specifically, we took inspiration 
from the biosynthesis of the dipyrroloquinoline alkaloids 7 and 
8 to design and develop NPP 9 as a new, broadly applicable 
amine donor. NPP 9 is easily prepared on multigram scale and 
displays excellent activity across an unprecedented range of pH 
and temperatures with both wild-type and commercially 
available, engineered TAs. NPP 9 works at near equimolar 
quantities even with challenging amine acceptors and 
industrially relevant substrates. The insolubility of the NPP by-
product 10 allows for easy identification of TA activity and 
facilitates simple removal by filtration. We anticipate that the 
broad range of reaction conditions under which NPP 9 operates 
will facilitate its widespread use in the biocatalytic preparation 
of chiral amines. A full review of the most popular amine donors 
(see Supplementary Section 2.18) suggests that the properties 
of NPP 9 that we have outlined in this study will see it rapidly 
become the preferred amine donor for biocatalytic 
transamination reactions. To that end, researchers interested in 
using NPP 9 can contact us to request a sample. 
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